Avammune at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
Avammune brings 2 presentations to ENA 2026 in Barcelona. Its posters centre on combining its ADAR1 and ENPP1 inhibitors with other treatments. The oral ADAR1 p150 inhibitors AVA-ADR-568/598 pair with anti-PD-1 in interferon-high melanoma models, and the ENPP1 inhibitor AVA-NP-695 works in synergy with DNA damage response inhibitors in osteosarcoma and Ewing sarcoma models.
| Organization | ENA 2026 Attendance |
|---|---|
Avammune Bengaluru, India | |
Develops small-molecule cancer therapies, including ADAR1 and ENPP1 inhibitors that boost immune responses. | Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm |
Instantly find 20 buyers from Avammune
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction